Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Genomic and transcriptomic signatures of extramedullary multiple myeloma reveal possible drivers of therapeutic resistance

View Full Paper
Ask AI
Bookmark
Share

Authors

CDCatherine DuaneMOMichael O’DwyerARAdam Roche

Discussion

Loading...

Member takes

Overview

Genomic analysis shows increased tumor mutational burden in extramedullary multiple myeloma, highlighting potential therapeutic targets for improved progression free survival.

Key Points

  • Therapeutic resistance is linked to the distinct genomic profile of extramedullary multiple myeloma.
  • Significant copy number variation was observed in pathways governing immune evasion and epithelial-mesenchymal transition.
  • Glycosylation changes, particularly ST3GAL1 activity, may mediate treatment responses in multiple myeloma.
  • The study points to potential therapeutic targets that could enhance progression free survival in EMD patients.

Cite This Study

Duane et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236de8ahttps://doi.org/10.1182/blood-2025-2175
View Full Paper
Ask AI
Bookmark
Share